EYPT
Eyepoint Pharmaceuticals Inc
4.10$
+1.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.8% | 38.8% | -1,007.2% | -271.8% | -374.1% | -278.4% | -41.9% | -135.6% | -157.0% | 4.1% | -291.7% | -765.4% | |
| 3.3% | 3.4% | 50.3% | 10.8% | 19.6% | 12.8% | 7.7% | 7.5% | 5.9% | 1.0% | 3.6% | 7.4% | |
| 7.4% | 8.1% | 151.6% | 32.6% | 67.7% | 22.4% | 16.1% | 20.2% | 34.2% | 26.2% | 84.9% | 88.8% | |
| 7.4% | 8.1% | 151.6% | 384.4% | 839.0% | 46.3% | 21.6% | 18.0% | 92.7% | – | – | – | |
| 3.8% | 7.8% | 19.6% | 3.3% | -16.1% | -61.6% | 58.5% | -4.7% | -7.3% | 128.0% | -64.2% | -107.7% | |
| 0.9% | 0.6% | 7.0% | 1.9% | 1.8% | 1.0% | 1.1% | 0.4% | 5.2% | 7.6% | 9.4% | 10.5% | |
| 0.2% | -16.8% | 838.1% | -224.0% | -288.4% | -1.0% | -1.1% | -89.7% | -41.7% | -7.2% | -506.9% | 218.6% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.9% | 64.0% | 524.9% | 557.3% | -3.3% | -0.6% | -0.3% | -0.4% | -0.7% | -0.4% | – | – | |
| 75.3% | 75.3% | 1,234.6% | 247.4% | 341.5% | 127.4% | -42.5% | -0.4% | -1.6% | -88.0% | -0.2% | -0.3% | |
| 71.7% | 64.0% | 524.9% | 112.8% | 498.7% | 166.3% | 108.9% | 587.2% | -1.7% | 406.5% | 379.0% | 553.5% | |
| 31.8% | 14.3% | -235.1% | 21.0% | 373.6% | -113.2% | 65.9% | 361.9% | -200.4% | 403.4% | -419.6% | 6.7% | |
| -41.1% | 38.2% | -1,014.1% | -273.7% | -375.9% | -279.5% | -43.0% | -136.0% | -162.2% | -3.5% | -301.1% | -775.8% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.